Natera, shared a post on X:
“We’re partnering with Aveta Biomics on a new global Phase 3 trial to help patients with head and neck cancer.
Together, we’re combining our Signatera™ test, which detects molecular residual disease (MRD), with Aveta’s APG-157 immunotherapy. The trial will incorporate serial Signatera testing to assess MRD and treatment response throughout therapy and follow-up. This partnership has the potential to advance the field and improve care for patients with head and neck cancer, which affects nearly 950,000 people globally each year.”
Other articles about Head and Neck Cancer on OncoDaily.